These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

725 related items for PubMed ID: 10063997

  • 1. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A, Schulman S, Varon D, Martinowitz U, Kenet G, Gitel S, Inbal A.
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA, Association of Hemophilia Clinic Directors of Canada.
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lippi G, Manzato F, Bertuzzo D, Gandini G.
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [Abstract] [Full Text] [Related]

  • 4. Acquired von Willebrand disease--hemostatic management of major orthopedic surgery with high-dose immunoglobulin, desmopressin, and continuous factor concentrate infusion.
    Frank RD, Kunz D, Wirtz DC.
    Am J Hematol; 2002 May; 70(1):64-71. PubMed ID: 11994985
    [Abstract] [Full Text] [Related]

  • 5. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ, van Vliet HH, Berneman Z, Schroyens W, Gadisseur A.
    Acta Haematol; 2009 May; 121(2-3):167-76. PubMed ID: 19506363
    [Abstract] [Full Text] [Related]

  • 6. Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.
    Auerswald G, Kreuz W.
    Haemophilia; 2008 Nov; 14 Suppl 5():39-46. PubMed ID: 18786009
    [Abstract] [Full Text] [Related]

  • 7. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 8. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ, Berneman ZN, van der Planken M, Schroyens W, Budde U, van Vliet HH.
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [Abstract] [Full Text] [Related]

  • 9. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U, Metzner HJ, Müller HG.
    Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ, Lloyd J, Rowell J, Baker R, Rickard K, Kershaw G, Street A, Scarff K, Barrese G, Maher D, McLachlan AJ.
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [Abstract] [Full Text] [Related]

  • 11. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, van de Velden A, Berneman Z.
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [Abstract] [Full Text] [Related]

  • 12. Successful surgical haemostasis in patients with von Willebrand disease with Koate DVI.
    Viswabandya A, Mathews V, George B, Nair SC, Baidya S, Mammen JJ, Chandy M, Srivastava A.
    Haemophilia; 2008 Jul; 14(4):763-7. PubMed ID: 18445014
    [Abstract] [Full Text] [Related]

  • 13. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.
    Dunkley S, Baker RI, Pidcock M, Price J, Seldon M, Smith M, Street A, Maher D, Barrese G, Stone C, Lloyd J.
    Haemophilia; 2010 Jul 01; 16(4):615-24. PubMed ID: 20331755
    [Abstract] [Full Text] [Related]

  • 14. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
    Hernandez-Navarro F, Quintana M, Jimenez-Yuste V, Alvarez MT, Fernandez-Morata R.
    Haemophilia; 2008 Sep 01; 14(5):963-7. PubMed ID: 18624696
    [Abstract] [Full Text] [Related]

  • 15. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
    Berntorp E, Archey W, Auerswald G, Federici AB, Franchini M, Knaub S, Kreuz W, Lethagen S, Mannucci PM, Pollmann H, Scharrer I, Hoots K.
    Eur J Haematol Suppl; 2008 May 01; (70):3-35. PubMed ID: 18380871
    [Abstract] [Full Text] [Related]

  • 16. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J, López-Fernández MF, Fraga EL, Trillo AR, Pérez-Rodríguez MA.
    Blood Coagul Fibrinolysis; 2009 Mar 01; 20(2):89-100. PubMed ID: 19786936
    [Abstract] [Full Text] [Related]

  • 17. Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate).
    Auerswald G, Eberspächer B, Engl W, Güthner C, Koksch M, Kreuz W, Nimtz A, Pindur G, Scheel H, Schreiber JD, Siekmann J, Turecek PL, Wolf HH.
    Semin Thromb Hemost; 2002 Apr 01; 28(2):203-14. PubMed ID: 11992243
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score.
    Federici AB, Barillari G, Zanon E, Mazzucconi MG, Musso R, Targhetta R, Mannucci PM.
    Haemophilia; 2010 Jan 01; 16(1):101-10. PubMed ID: 19811543
    [Abstract] [Full Text] [Related]

  • 19. Long-term prophylaxis with intermediate-purity factor VIII concentrate (Haemate P) in a patient with type 3 von Willebrand disease and recurrent gastrointestinal bleeding.
    Coppola A, Cimino E, Conca P, De Simone C, Tufano A, Tarantino G, Cerbone AM, Minno G.
    Haemophilia; 2006 Jan 01; 12(1):90-4. PubMed ID: 16409182
    [Abstract] [Full Text] [Related]

  • 20. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E, Windyga J, European Wilate Study Group.
    Haemophilia; 2009 Jan 01; 15(1):122-30. PubMed ID: 19149848
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.